The average patient with advanced pancreatic cancer won’t live longer than a year. Photo: Alamy
Pancreatic cancer: new drug therapy significantly slows the spread of the disease, study finds
- A third of the patients who received the medication olaparib were still alive two years into the clinical trial
- Those patients had their disease under control for almost twice as long as those who received the placebo
Topic |
Health and wellness
The average patient with advanced pancreatic cancer won’t live longer than a year. Photo: Alamy